Sun Pharma declines on buzz of drug recall

Image
Capital Market
Last Updated : Mar 10 2014 | 11:57 PM IST

Sun Pharmaceutical Industries fell 1.98% to Rs 600.05 at 14:04 IST on BSE on reports the company is voluntarily recalling 2,528 bottles of its generic version of diabetes drug Glumetza from US-based Santarus Inc.

Meanwhile, the BSE Sensex was up 20.58 points, or 0.09%, to 21,940.37.

On BSE, so far 1.18 lakh shares were traded in the counter, compared with an average volume of 1.34 lakh shares in the past one quarter.

The stock hit a high of Rs 611 and a low of Rs 595.05 so far during the day. The stock hit a record high of Rs 653.10 on 3 March 2014. The stock hit a 52-week low of Rs 405.50 on 1 April 2013.

The stock had underperformed the market over the past one month till 7 March 2014, rising 1.80% compared with the Sensex's 7.57% rise. The scrip had, however, outperformed the market in past one quarter, rising 5.16% as against Sensex's 4.40% rise.

The large-cap company has an equity capital of Rs 207.12 crore. Face value per share is Re 1.

According to reports, Sun Pharmaceutical Industries began recalling the bottles of metformin HCL extended-release tables in the United States on 28 January 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin.

The company did not expect a significant impact by the recall, reports said.

The US Food and Drug Administration (USFDA) classified the recall as a "Class II," which signifies a remote chance of severe adverse consequences or death due to the product flaw, reports added.

Sun Pharma's consolidated net profit surged 73.73% to Rs 1531.09 crore on 51.59% increase in total income to Rs 4446.82 crore in Q3 December 2013 over Q3 December 2012.

Sun Pharmaceutical Industries is an international specialty pharmaceutical company with over 72% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 10 2014 | 2:15 PM IST

Next Story